NCT05372380View on ClinicalTrials.gov

A Study to Evaluate Drug-drug Interactions Between BR1017-1 and BR1017-2 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 9, 2022

Primary Completion Date

June 4, 2022

Study Completion Date

June 30, 2022

Conditions
HypertensionHypercholesterinemia
Interventions
DRUG

BR1017-1

Administration to the F/F+AE group: BR1017-1 will be administered 1 tablet QD, five-day repeat dose

DRUG

BR1017-2

Administration to the AE group: BR1017-2 will be administered 1 tablet QD, 9-day repeat dose Administration to the F+AE group: BR1017-2 will be administered 1 tablet once QD, 5-day repeat dose.

Trial Locations (1)

13520

CHA Bundang Medical Center, CHA University, Gyeonggi-do

Sponsors
All Listed Sponsors
lead

Boryung Pharmaceutical Co., Ltd

INDUSTRY